Evaluating strategic options for iopofosine I 131 a late-stage clinical program with compelling Phase 2 data and a substantial market ...
Anixa's focus on breast and ovarian cancer immunotherapies shows promise but lacks substantial data. Find out why I ...
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the ...
Thirty years after the sequencing of the BRCA1 cancer-associated gene, access to genetic tests and awareness about its risks ...
The Amyloidosis market was $3.6 billion in 2017, and is expected to reach $6 billion in 2025, according to Grand View Research.
Traumatic brain injury (TBI) is a leading cause of death and disability among young people in the United States and is the most devastating survivable injury in modern warfare, according to the ...
Technologies developed by UC San Diego and Scripps Research teams will map the human eye-brain connectome, extend the ...
Thermo Fisher's patent activity and acquisition strategy support growth. Find out why TMO stock is poised for continued ...
In a comprehensive Genomic Press Interview, distinguished psychiatrist Professor Peter Falkai suggests promising new ...
ShiraTronics has commenced the pivotal RELIEV-CM2 CLINICAL Study of its implantable neuromodulation therapy, designed for ...